HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues.

Abstract
Bernserazide (D,L-serine 2-[2,3,4-trihydroxybenzyl]-hydrazide) as been shown to inhibit the clorgyline-resistant amine oxidase (CRAO) activities which metabolize benzylamine in homogenates of rat aorta, heart and brown adipose tissue. In vitro studies showed a concentration- and time-dependent inhibition of CRAO in heart and aorta which was reversed by dialysis for 18hr. At high concentrations (10(-4)-10(-3)M) benserazide appeared to increase enzyme activity towards and occasionally above control value. These increases became more prominent after long periods of preincubation (especially in the presence of saturating benzylamine concentrations) and remained after dialysis of those homogenates preincubated with benserazide. The administration of benserazide for one or seven days in daily doses of 5-150 mg/kg also inhibited CRAO activity in vivo in a dose-dependent manner, with greater inhibition after seven days treatment. Reversal of inhibition, by dialysis of tissue homogenates from benserazide-treated rats, was much slower than was found with homogenates incubated in vitro with the drug. After benserazide administration to rats, MAO-A activity towards 5-hydroxytryptamine was generally not inhibited, and in fact was significantly increased in some cases. The administration of L-DOPA (250 mg/kg) together with benserazide (40 mg/kg) resulted in a similar degree of CRAO inhibition in aorta and heart to that seen after benserazide alone. These findings are discussed with regard to the use of these drugs in the therapy of Parkinson's Disease, although the paucity of information about the physiological function of CRAO makes the significance of its inhibition by benserazide unclear.
AuthorsG A Lyles, B A Callingham
JournalBiochemical pharmacology (Biochem Pharmacol) Vol. 31 Issue 7 Pg. 1417-24 (Apr 01 1982) ISSN: 0006-2952 [Print] England
PMID7092930 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Hydrazines
  • Propylamines
  • Levodopa
  • Benserazide
  • Amine Oxidase (Copper-Containing)
  • Monoamine Oxidase
  • Oxidoreductases Acting on CH-NH Group Donors
  • Clorgyline
Topics
  • Amine Oxidase (Copper-Containing)
  • Animals
  • Benserazide (pharmacology)
  • Cardiovascular System (enzymology)
  • Clorgyline (pharmacology)
  • Drug Resistance
  • Hydrazines (pharmacology)
  • In Vitro Techniques
  • Kinetics
  • Levodopa (pharmacology)
  • Male
  • Monoamine Oxidase (metabolism)
  • Oxidoreductases Acting on CH-NH Group Donors (antagonists & inhibitors)
  • Propylamines (pharmacology)
  • Rats
  • Rats, Inbred Strains

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: